{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:27:41Z","timestamp":1791412061486,"version":"4.3.3"},"reference-count":38,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.vaccine.2023.08.079","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:46:50Z","timestamp":1693874810000},"page":"6227-6238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Background rates of adverse events of special interest for COVID-19 vaccines: A multinational Global Vaccine Data Network (GVDN) analysis"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-4561","authenticated-orcid":false,"given":"A.","family":"Phillips","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Artama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Clothier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Cullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0066-2218","authenticated-orcid":false,"given":"L.","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0864-4321","authenticated-orcid":false,"given":"S.","family":"Escolano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1072-7700","authenticated-orcid":false,"given":"A.","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gidding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Giglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Junker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4344-9567","authenticated-orcid":false,"given":"W.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Janjua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9793-113X","authenticated-orcid":false,"given":"S.","family":"Nasreen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4947-6208","authenticated-orcid":false,"given":"M.","family":"Naus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Naveed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pillsbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Stowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8551-4240","authenticated-orcid":false,"given":"T.","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9905-2035","authenticated-orcid":false,"given":"J.","family":"Buttery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Petousis-Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7509-9127","authenticated-orcid":false,"given":"A.","family":"Hviid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.08.079_b0005","series-title":"WHO Coronavirus (COVID-19) Dashboard","author":"World Health Organisation","year":"2023"},{"key":"10.1016\/j.vaccine.2023.08.079_b0010","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMp2034334","article-title":"On the shoulders of giants \u2014 from jenner\u2019s cowpox to mRNA covid vaccines","volume":"384","author":"Desmond","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.08.079_b0015","doi-asserted-by":"crossref","first-page":"e003540","DOI":"10.1136\/bmjgh-2020-003540","article-title":"Methodological frontiers in vaccine safety: qualifying available evidence for rare events, use of distributed data networks to monitor vaccine safety issues, and monitoring the safety of pregnancy interventions","volume":"6","author":"Dodd","year":"2021","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.vaccine.2023.08.079_b0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12916-021-02059-5","article-title":"Evaluation of the safety profile of COVID-19 vaccines: a rapid review","volume":"19","author":"Wu","year":"2021","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2023.08.079_b0025","series-title":"Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant]) \u2013 COVID-19 Vaccine AstraZeneca (other viral vaccines)","author":"European Medicines Agency","year":"2021"},{"key":"10.1016\/j.vaccine.2023.08.079_b0030","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1001\/jama.2021.7517","article-title":"US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021","volume":"325","author":"See","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.08.079_b0035","series-title":"Global Advisory Committee on Vaccine Safety (GACVS) review of latest evidence of rare adverse blood coagulation events with AstraZeneca COVID-19 Vaccine (Vaxzevria and Covishield)","author":"World Health Organisation","year":"2021"},{"key":"10.1016\/j.vaccine.2023.08.079_b0040","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA covid-19 vaccine in a nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.08.079_b0045","series-title":"FDA and CDC Lift Recommended Pause on Johnson & Johnson (Janssen) COVID-19 Vaccine Use Following Thorough Safety Review","author":"US Food and DrugAdministration","year":"2021"},{"key":"10.1016\/j.vaccine.2023.08.079_b0050","series-title":"COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS): updated guidance regarding myocarditis and pericarditis reported with COVID-19 mRNA vaccines","author":"World Health Organisation","year":"2021"},{"key":"10.1016\/j.vaccine.2023.08.079_b0055","series-title":"AstraZeneca ChAdOx1-S COVID-19 vaccine: Updated safety advisory - rare and unusual blood clotting syndrome (thrombosis with thrombocytopenia)","author":"Therapeutic Goods Administration","year":"2021"},{"key":"10.1016\/j.vaccine.2023.08.079_b0060","doi-asserted-by":"crossref","first-page":"E1529","DOI":"10.1503\/cmaj.220676","article-title":"Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination: a population-based cohort study","volume":"194","author":"Naveed","year":"2022","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2023.08.079_b0065","series-title":"Covid-19 vaccines: safety surveillance manual","author":"World Health Organisation","year":"2020"},{"key":"10.1016\/j.vaccine.2023.08.079_b0070","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.vaccine.2021.03.016","article-title":"The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety","volume":"39","author":"Black","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.079_b0075","series-title":"ACIP Meeting Information","author":"Centers for Disease Control and Prevention","year":"2023"},{"key":"10.1016\/j.vaccine.2023.08.079_b0080","series-title":"Coronavirus vaccine - summary of Yellow Card reporting London","author":"Medicines and Healthcare Products Regulatory Agency","year":"2023"},{"key":"10.1016\/j.vaccine.2023.08.079_b0085","series-title":"Weekly Safety Reports","author":"Therapeutic Goods Administration","year":"2023"},{"key":"10.1016\/j.vaccine.2023.08.079_b0090","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.vaccine.2022.11.003","article-title":"Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States,2019\u20132020","volume":"41","author":"Moll","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.079_b0095","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vaccine.2022.11.031","article-title":"Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study","volume":"41","author":"Willame","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.079_b0100","series-title":"Global COVID Vaccine Safety (GCoVS) [Internet]","author":"Global Vaccine Data Network","year":"2022"},{"key":"10.1016\/j.vaccine.2023.08.079_b0105","series-title":"Background rates of adverse events of special interest following COVID-19 vaccination study protocol [Internet]","author":"Global Vaccine Data Network","year":"2022"},{"key":"10.1016\/j.vaccine.2023.08.079_b0110","series-title":"Background rates dashboard [dataset on the Internet]","author":"Global Vaccine Data Network. GVDN","year":"2022"},{"key":"10.1016\/j.vaccine.2023.08.079_b0115","series-title":"SO2-D2.1.2 Priority list of COVID-19 adverse events of special interest: quarterly update","author":"Safety Platform for Emergency vACcines (SPEAC)","year":"2020"},{"key":"10.1016\/j.vaccine.2023.08.079_b0120","unstructured":"World Health Organisation. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on reports of Guillain-Barr\u00e9 Syndrome (GBS) following adenovirus vector COVID-19 vaccines. Geneva: WHO; 2021 [accessed 5 May 2023]. Available from: https:\/\/www.who.int\/news\/item\/26-07-2021-statement-of-the-who-gacvs-covid-19-subcommittee-on-gbs."},{"key":"10.1016\/j.vaccine.2023.08.079_b0125","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41591-021-01408-4","article-title":"First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland","volume":"27","author":"Simpson","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2023.08.079_b0130","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/oxfordjournals.aje.a115507","article-title":"A simple method to calculate the confidence interval of a standardized mortality ratio (SMR)","volume":"131","author":"Ulm","year":"1990","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2023.08.079_b0135","series-title":"Statistics in epidemiology: methods, techniques and applications Boca Raton","author":"Sahai","year":"1996"},{"key":"10.1016\/j.vaccine.2023.08.079_b0140","doi-asserted-by":"crossref","first-page":"e052019","DOI":"10.1136\/bmjopen-2021-052019","article-title":"Background incidence rates of hospitalisations and emergency department visits for thromboembolic and coagulation disorders in Ontario, Canada for COVID-19 vaccine safety assessment: a population-based retrospective observational study","volume":"11","author":"Nasreen","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2023.08.079_b0145","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/pds.5419","article-title":"Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: Incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries","volume":"31","author":"Burn","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2023.08.079_b0150","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1016\/j.vaccine.2022.04.065","article-title":"Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance","volume":"40","author":"Nasreen","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.079_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2023.04.041","article-title":"Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines","author":"Pillsbury","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.079_b0160","doi-asserted-by":"crossref","first-page":"n1435","DOI":"10.1136\/bmj.n1435","article-title":"Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study","volume":"373","author":"Li","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2023.08.079_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101932","article-title":"Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study","volume":"58","author":"Voss","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2023.08.079_b0170","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1016\/j.vaccine.2021.05.016","article-title":"U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines","volume":"39","author":"Gubernot","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.079_b0175","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/19418744221123208","article-title":"Impact of the COVID-19 pandemic on diagnostic frequency of febrile seizures: an electronic health record database observational study","volume":"13","author":"Cadet","year":"2023","journal-title":"Neurohospitalist"},{"key":"10.1016\/j.vaccine.2023.08.079_b0180","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/CIRCULATIONAHA.122.060785","article-title":"Association of COVID-19 with major arterial and venous thrombotic diseases: a population-wide cohort study of 48 million adults in England and wales","volume":"146","author":"Knight","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2023.08.079_b0185","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/bmjebm-2020-111527","article-title":"SARS-CoV-2 myocarditis: what physicians need to know","volume":"27","author":"Khalil","year":"2022","journal-title":"BMJ Evid-Based Med"},{"key":"10.1016\/j.vaccine.2023.08.079_b0190","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1056\/NEJMoa2110737","article-title":"Myocarditis after Covid-19 vaccination in a large health care organization","volume":"385","author":"Witberg","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23010459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23010459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:30:24Z","timestamp":1759404624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23010459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":38,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0264410X23010459"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.08.079","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Background rates of adverse events of special interest for COVID-19 vaccines: A multinational Global Vaccine Data Network (GVDN) analysis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.08.079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}